Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 31, 2020 16:08 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, July 31, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity...
Bellicum to Report Second Quarter 2020 Financial Results and Provide Corporate Update
July 30, 2020 16:05 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, July 30, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced it will...
Bellicum Announces Publication of Data for GoCAR-NK™ Cell Program
May 27, 2020 16:05 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, May 27, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the...